Segment Reporting – Chemicals*

XLS

 

 

 

 

 

 

 

 

 

 

Merck Millipore

Performance Materials

EUR million

Q3
2010

Q3
2009

Jan.-Sep.
2010

Jan.-Sep.
2009

Q3
2010

Q3
2009

Jan.-Sep.
2010

Jan.-Sep.
2009

*

As a result of the acquisition of Millipore, the Chemicals business sector was reorganized. The previous year’s figures have been adjusted.

**

Figures for 2009 have been adjusted for the disclosure of commission income as well as royalty and commission expenses.

***

Actual year as at September 30, 2010 – previous year as at December 31, 2009.

Sales

571.8

224.2

1,079.7

688.8

344.6

279.5

1,056.7

728.3

Royalty and commission income**

1.9

2.4

5.6

6.6

1.1

2.3

5.6

7.5

Total revenues

573.7

226.7

1,085.3

695.5

345.7

281.8

1,062.3

735.8

Gross margin

295.7

104.0

565.2

324.8

236.4

138.1

713.4

338.7

Marketing and selling expenses**

–141.3

–57.2

–271.7

–171.8

–29.9

–23.3

–85.5

–72.6

Royalty and commission expenses**

–3.2

–2.0

–6.5

–4.9

–1.9

–0.6

–7.5

–2.3

Administration expenses

–27.0

–10.2

–50.6

–32.8

–9.8

–7.3

–28.2

–25.9

Other operating expenses and income

–35.7

–5.9

–97.6

–15.9

–9.2

–5.6

–46.5

–26.6

Research and development

–30.9

–8.2

–46.0

–24.0

–32.5

–27.2

–92.1

–82.1

Operating result

10.0

20.2

45.2

74.6

151.9

72.6

449.4

125.0

Exceptional items

–

–

–

–

–

–

–

1.2

Earnings before interest and tax (EBIT)

10.0

20.2

45.2

74.6

151.9

72.6

449.4

126.2

Net operating assets***

–

–

6,493.1

781.2

–

–

1,259.1

1,176.3

Segment liabilities***

–

–

–348.7

–111.5

–

–

–145.3

–118.7

Capital spending on property, plant and equipment

23.6

13.1

45.5

37.4

19.5

14.1

42.9

53.5

Investments in intangible assets

2.1

0.7

4.3

3.6

0.7

0.4

2.1

5.0

Depreciation

–70.3

–11.8

–95.5

–34.0

–24.5

–20.5

–69.5

–63.1

Impairment losses

–1.6

–

–1.6

–

–

–7.8

–16.4

–8.0

Net cash flows from operating activities

29.9

56.1

95.5

143.1

184.0

131.2

468.0

242.3

Net cash flows from investing activities

–4,861.8

–12.4

–4,886.7

–38.5

–25.2

–33.3

–49.5

–77.0

Free cash flow

–4,831.9

43.7

–4,791.2

104.6

158.9

97.9

418.5

165.4

Underlying free cash flow

101.8

43.7

142.6

104.6

165.4

116.8

425.0

184.2

FCR in %

17.8

19.3

13.1

15.0

47.9

41.4

40.0

25.0

ROS in %

1.7

8.9

4.2

10.7

43.9

25.8

42.3

17.0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Chemicals

EUR million

 

 

 

 

Q3
2010

Q3
2009

Jan.-Sep.
2010

Jan.-Sep.
2009

Sales

 

 

 

 

916.4

503.7

2,136.4

1,417.1

Royalty and commission income**

 

 

 

 

3.0

4.8

11.1

14.2

Total revenues

 

 

 

 

919.4

508.5

2,147.5

1,431.3

Gross margin

 

 

 

 

532.1

242.1

1,278.6

663.5

Marketing and selling expenses**

 

 

 

 

–171.3

–80.4

–357.2

–244.4

Royalty and commission expenses**

 

 

 

 

–5.1

–2.6

–14.0

–7.2

Administration expenses

 

 

 

 

–36.8

–17.5

–78.9

–58.6

Other operating expenses and income

 

 

 

 

–45.0

–11.6

–144.1

–42.5

Research and development

 

 

 

 

–63.5

–35.4

–138.0

–106.2

Operating result

 

 

 

 

161.8

92.8

494.6

199.6

Exceptional items

 

 

 

 

–

–

–

1.2

Earnings before interest and tax (EBIT)

 

 

 

 

161.8

92.8

494.6

200.8

Net operating assets***

 

 

 

 

–

–

7,752.2

1,957.4

Segment liabilities***

 

 

 

 

–

–

–494.1

–230.2

Capital spending on property, plant and equipment

 

 

 

 

43.1

27.2

88.5

90.9

Investments in intangible assets

 

 

 

 

2.8

1.0

6.4

8.6

Depreciation

 

 

 

 

–94.8

–32.3

–164.9

–97.1

Impairment losses

 

 

 

 

–1.6

–7.8

–18.0

–8.0

Net cash flows from operating activities

 

 

 

 

213.9

187.4

563.5

385.5

Net cash flows from investing activities

 

 

 

 

–4,886.9

–45.8

–4,936.2

–115.5

Free cash flow

 

 

 

 

–4,673.0

141.6

–4,372.7

269.9

Underlying free cash flow

 

 

 

 

267.3

160.5

567.6

288.8

FCR in %

 

 

 

 

29.1

31.6

26.4

20.2

ROS in %

 

 

 

 

17.6

18.2

23.0

13.9